Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHarvard Pilgrim prior auth formulary listings | Op…
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    Prior authorization medical necessity guidelines — formulary product listings (partial)

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Section of Harvard Pilgrim Health Care's 2026 prior authorization medical necessity guidelines listing pharmacy products and summarizing prior authorization criteria, documentation, step therapy and prescriber restrictions for selected specialty drugs.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyPrior authorization medical necessity guidelines — formulary product listings (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionPrescribers must submit prior authorization with documented diagnosis and required prior-therapy trials or specialist prescriber information as specified for each drug.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    15+document chunks in this partial extract
    2 yearscoverage duration noted
    someprerequisite therapy varies
    ~20products shown (partial)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria — Product-Specific Requirements

    inv-01: Abilify Mycite — Initial Therapy — coverage when criteria met

    Covered when ALL of the following are met:

    Abilify Mycite initial criteria: Member has a documented diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia; documentation of worsening symptoms while on oral aripiprazole; prescribing physician is a psychiatrist; prerequisite therapy: prior use of oral aripiprazole (prerequisite Part D drug) has been attempted prior to this request; coverage duration is limited to 2 years.

    From product PA summary (chunk 5).

    inv-02: Abiraterone — Initial Therapy — coverage when criteria met

    Covered when ALL of the following are met:

    Abiraterone initial criteria: Member has a documented diagnosis of metastatic castration-resistant prostate cancer (CRPC) or metastatic high-risk castration-sensitive prostate cancer; abiraterone is being used in combination with prednisone; prescribing physician is an oncologist or urologist; coverage duration is limited to 2 years.

    From product PA summary (chunk 10).

    inv-03: Humira and Biosimilars - Indication and Prescriber Requirements — high-level summaries (partial)

    High-level indication and prescriber summaries (partial):

    Humira Indication Requirements: Member has a documented diagnosis specific to the requested indication (examples include ankylosing spondylitis, Crohn's disease, moderately-to-severely active ulcerative colitis, moderate-to-severe hidradenitis suppurativa, moderate-to-severe plaque psoriasis with prior topical/systemic therapy failure, psoriatic arthritis, rheumatoid arthritis with trial/failure/intolerance/contraindication to one conventional therapy, polyarticular juvenile idiopathic arthritis with trial/failure/intolerance/contraindication to one conventional therapy, or non-infectious uveitis).

    Prescriber specialty or consultation required by indication (e.g., dermatologist, gastroenterologist, ophthalmologist, rheumatologist); coverage duration typically 2 years; some Humira entries require prerequisite Part D therapy (chunk 29).

    inv-04: Aimovig - Migraine — requirements (partial)

    Covered when ALL of the following are met:

    Aimovig Initial and Subsequent Approval: Initial approval: documented diagnosis of migraine. Subsequent approval: documentation of clinically significant reduction in migraine days per month from baseline as determined by the prescriber.

    Initial approval duration: 6 months; subsequent approval: 2 years; no prerequisite Part D drug required (chunk 32).

    inv-05: Akeega - Prostate Cancer — requirements (partial)

    Covered when ALL of the following are met:

    Akeega oncology criteria: Member has documented metastatic prostate cancer with deleterious or suspected deleterious BRCA mutation per the listed contexts (metastatic, castration‑resistant BRCA-mutated or metastatic, castration‑sensitive BRCA2-mutated), the requested drug is being used in combination with prednisone and other regimen specifications are met; prescribing physician is an oncologist; coverage duration 2 years.

    From product PA summary (chunk 35).

    inv-06: Alecensa - Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Alecensa initial criteria: Member has documented ALK‑positive metastatic non‑small cell lung cancer (NSCLC) or the drug is being used as adjuvant treatment following resection of an ALK‑positive tumor; prescribing physician is an oncologist; coverage duration 2 years.

    Prerequisite Part D drug not required (chunk 38).

    inv-07: Alunbrig - Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Alunbrig initial criteria: Member has documented ALK‑positive metastatic non‑small cell lung cancer (NSCLC); prescribing physician is an oncologist; coverage duration 2 years.

    Prerequisite Part D drug not required (chunk 43).

    inv-08: Alosetron - Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Alosetron initial criteria: Member is female with documented severe diarrhea‑predominant irritable bowel syndrome; coverage duration 2 years; prescribing physician documented as required per request.

    Prerequisite Part D drug not required (chunk 41).

    inv-09: Arcalyst - Indications — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Arcalyst indications: Member has one of the following documented diagnoses: Cryopyrin‑Associated Periodic Syndrome (including Familial Cold Autoinflammatory Syndrome or Muckle‑Wells), deficiency of interleukin‑1 receptor antagonist (for maintenance of remission in patients ≥10 kg), OR recurrent pericarditis with indication‑specific justification.

    Coverage duration 2 years; prerequisite Part D drug not required (chunk 45).

    inv-10: Arikayce - Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Arikayce initial criteria: Member has documented Mycobacterium avium complex (MAC) lung disease and Arikayce is being used as part of a combination antibacterial regimen; member did not achieve at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen; prescribed by or in consultation with an infectious disease or appropriate specialist; coverage duration 2 years.Minimum 6 months background regimen; not achieving ≥2 negative sputum cultures

    Prerequisite Part D drug required (background multidrug regimen) (chunk 48).

    inv-11: Armodafinil/Modafinil - Indications — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Armodafinil/Modafinil indications: Member has a documented diagnosis of narcolepsy OR excessive sleepiness associated with obstructive sleep apnea OR shift‑work sleep disorder; coverage duration 2 years.

    Not approved for generalized fatigue, jet‑lag, or sleep‑deprivation not associated with a covered diagnosis (chunk 52).

    inv-12: Augtyro - Indications — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Augtyro indications: Member has documented non‑small cell lung cancer (NSCLC) OR an NTRK gene fusion–positive solid tumor that is locally advanced/metastatic or where surgical resection would cause severe morbidity, AND disease has progressed following treatment or there is no satisfactory alternative therapy.

    Prerequisite Part D drug not required in excerpt (chunk 55).

    inv-13: Augtyro Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Augtyro initial criteria: Documented NSCLC or NTRK fusion–positive solid tumor that is locally advanced or metastatic or where surgical resection would cause severe morbidity, AND disease has progressed following treatment or there is no satisfactory alternative therapy.

    From Augtyro product summary (chunk 55).

    inv-14: Austedo Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Austedo indications: Member has documented diagnosis of tardive dyskinesia OR chorea associated with Huntington's disease as specified in the product listing.

    Coverage duration and details per product summary (chunk 60).

    inv-15: Avmapki Fakzynja Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Avmapki Fakzynja criteria: Documented recurrent low‑grade serous ovarian cancer (LGSOC) AND presence of a KRAS mutation AND patient has received prior systemic therapy; coverage duration 2 years.

    Prerequisite Part D drug required per product summary (chunk 63).

    inv-16: Ayvakit Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Ayvakit indications: Member has documented PDGFRA Exon 18 mutation–positive unresectable or metastatic GIST OR advanced systemic mastocytosis (ASM/SM‑AHN/MCL) OR indolent systemic mastocytosis; prescribing physician must be an allergist, immunologist, or specified specialist; coverage duration 2 years.

    From product summary (chunk 66).

    inv-17: Balversa Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Balversa criteria: Member has documented locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations AND disease progressed during or after at least one line of systemic therapy AND prior PD‑1/PD‑L1 inhibitor therapy was given or member is not a candidate for PD‑1/PD‑L1 therapy; prescribing physician is an oncologist or urologist; coverage duration 2 years.

    Prerequisite Part D drug required (chunk 69).

    inv-18: Benlysta Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Benlysta criteria: Member has documented active, autoantibody‑positive systemic lupus erythematosus (e.g., ANA, anti‑dsDNA, anti‑Sm) or active lupus nephritis AND is concurrently taking standard therapy (antimalarials, corticosteroids, or immunosuppressives); prescribing physician is a nephrologist or rheumatologist; coverage duration 2 years.

    Benlysta will not be approved as monotherapy, for members with severe active lupus nephritis or severe active CNS lupus, for autoantibody‑negative members, or in combination with other biologics or IV cyclophosphamide (chunk 72).

    inv-19: Benlysta — Initial Therapy — (duplicate inventory entry)

    Covered when ALL of the following are met:

    Benlysta initial coverage: Member has active, autoantibody‑positive SLE or active lupus nephritis; member is concurrently taking standard therapy (antimalarials, corticosteroids, or immunosuppressives); prescriber is a nephrologist or rheumatologist; coverage duration 2 years.

    Exclusions: not approved as monotherapy, for severe active lupus nephritis or severe active CNS lupus, for autoantibody‑negative members, or combined with other biologics/IV cyclophosphamide (chunk 72).

    inv-20: Berinert — Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Berinert initial coverage: Member has a documented diagnosis of hereditary angioedema (HAE); prescribing physician is an allergist or immunologist; coverage duration 2 years.

    From product summary (chunk 75).

    inv-21: Besremi — Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Besremi initial coverage: Member has documented diagnosis of polycythemia vera; coverage duration 2 years.

    From product summary (chunk 78).

    inv-22: Bexarotene gel — Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Bexarotene gel initial coverage: Member has a documented diagnosis of cutaneous T‑cell lymphoma; prescribing physician is an oncologist or dermatologist; coverage duration 2 years.

    From product summary (chunk 81).

    inv-23: Bosulif — Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Bosulif indication options: Member has documented chronic phase Philadelphia chromosome‑positive (Ph+) CML (newly‑diagnosed or resistant/intolerant to at least one prior therapy such as imatinib) OR accelerated or blast phase Ph+ CML; prescribing physician is a hematologist or oncologist; coverage duration 2 years.

    Prerequisite Part D drug required (chunk 85).

    inv-24: Braftovi — Indication-Specific Criteria — Covered when ALL of the following are met (by indication)

    Covered when ALL of the following are met (by indication):

    Braftovi indication options: Metastatic colorectal cancer with BRAF V600E mutation to be taken in combination with cetuximab (with/without fluorouracil‑based chemotherapy) OR unresectable/metastatic melanoma with BRAF V600E or V600K mutation to be taken in combination with binimetinib OR metastatic NSCLC with BRAF V600E mutation to be taken in combination with binimetinib; prescribing physician must be an oncologist; coverage duration 2 years.

    Not indicated for wild‑type BRAF melanoma or wild‑type BRAF CRC (chunk 88).

    inv-25: Brukinsa — Indication-Specific Criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met (indication‑specific):

    Brukinsa indication options: Member has documented diagnosis of mantle cell lymphoma with at least one prior therapy OR relapsed/refractory marginal zone lymphoma with at least one anti‑CD20 regimen OR Waldenstrom's macroglobulinemia OR chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) OR relapsed/refractory follicular lymphoma in combination with obinutuzumab after two or more prior therapies; prescribing physician must be a hematologist or oncologist; coverage duration 2 years.

    Prerequisite Part D drug required for some indications (chunk 91).

    inv-26: Brukinsa - Covered with criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Brukinsa coverage criteria: Member has a documented eligible hematologic malignancy per listed indications and prior therapy history; prescribing physician is a hematologist or oncologist; coverage duration 2 years.

    Prerequisite Part D drug required for some indications (chunk 91).

    inv-27: Cabometyx - Covered with criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cabometyx coverage criteria: Member has a documented diagnosis corresponding to the requested indication (advanced renal cell carcinoma; locally advanced/metastatic differentiated thyroid cancer progressed after prior VEGFR‑targeted therapy; hepatocellular carcinoma with failure/contraindication/intolerance to sorafenib; or previously treated unresectable locally advanced/metastatic well‑differentiated pancreatic/extra‑pancreatic neuroendocrine tumors); prescribing physician must be an oncologist; coverage duration 2 years.

    Prerequisite Part D drug required (chunk 94).

    inv-28: Calquence - Covered with criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Calquence coverage criteria: Member has documented chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) OR mantle cell lymphoma (MCL) with prior therapy or meets listed untreated MCL exceptions; prescribing physician is a hematologist or oncologist; coverage duration 2 years.

    Prerequisite Part D drug required (chunk 97).

    inv-29: Caplyta - Covered with criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Caplyta coverage criteria: Member has diagnosis of bipolar depression OR major depressive disorder when used as adjunctive therapy with antidepressants; coverage and prescribing details per product summary.

    No prerequisite Part D drug required per excerpt (chunk 100).

    inv-30: Caprelsa - Covered with criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Caprelsa coverage criteria: Member has documented symptomatic or progressive medullary thyroid cancer with unresectable locally advanced disease; prescribing physician is an endocrinologist or oncologist; coverage duration 2 years.

    Prerequisite Part D drug not required (chunk 103).

    inv-31: Carglumic Acid - Covered with criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Carglumic Acid coverage criteria: Member has documented chronic or acute hyperammonemia due to N‑acetylglutamate synthase (NAGS) deficiency; coverage duration 2 years.

    Prerequisite Part D drug not required (chunk 106).

    inv-32: Cayston - Covered with criteria — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cayston coverage criteria: Member has documented cystic fibrosis AND evidence of Pseudomonas aeruginosa in the lungs; coverage duration 2 years.

    Prerequisite Part D drug not required per excerpt (chunk 109).

    inv-33: Cayston - Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cayston initial criteria: Documented diagnosis of cystic fibrosis AND evidence of Pseudomonas aeruginosa in the lungs; coverage duration 2 years.

    From Cayston PA summary (chunk 109).

    inv-34: Cobenfy Starter Pack - Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cobenfy Starter Pack initial criteria: Documented diagnosis of schizophrenia AND prescribing physician is a psychiatrist; coverage duration 2 years; approve continuation of prior therapy where noted.

    From product summary (chunk 113).

    inv-35: Cometriq - Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cometriq initial criteria: Documented diagnosis of progressive, metastatic medullary thyroid cancer AND prescribing physician is an oncologist; coverage duration 2 years.

    From product summary (chunk 116).

    inv-36: Copiktra - Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Copiktra initial criteria: Documented diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) AND patient has received at least two prior therapies; prescribing physician is a hematologist or oncologist; coverage duration 2 years.

    Prerequisite Part D drug required (chunk 119).

    inv-37: Cosentyx - Indication-specific Criteria — Covered when ALL relevant indication-specific criteria are met

    Covered when ALL relevant indication‑specific criteria are met:

    Cosentyx plaque psoriasis criteria: Documented moderate‑to‑severe plaque psoriasis AND failure or intolerance to at least one listed topical/systemic prior therapy; prescribed by or in consultation with a dermatologist; coverage duration 2 years.

    From Cosentyx PA summary (chunks 124–125).

    Cosentyx axial spondyloarthritis criteria: Documented active non‑radiographic axial spondyloarthritis with objective signs of inflammation (e.g., elevated CRP and/or sacroiliitis on MRI) AND a minimum one‑month trial and failure/contraindication/intolerance to two NSAIDs at maximally indicated doses; prescribed by or in consultation with a rheumatologist; coverage duration 2 years.minimum 1 month; two NSAID trials

    From product summary (chunks 124–125).

    inv-38: Cotellic — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cotellic main criteria: Documented unresectable or metastatic melanoma with a BRAF V600E or V600K mutation and being used in combination with vemurafenib (Zelboraf), OR documented histiocytic neoplasm when used as monotherapy; prescribing physician must be an oncologist; coverage duration 2 years.

    Exclusion: not indicated for wild‑type BRAF melanoma (chunk 128).

    inv-39: Cresemba — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Cresemba main criteria: Documented diagnosis of invasive aspergillosis or invasive mucormycosis; coverage duration 1 year.

    From product summary (chunk 131).

    inv-40: Danziten — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Danziten main criteria: Diagnosis of Philadelphia chromosome‑positive (Ph+) CML in chronic phase OR chronic/accelerated phase Ph+ CML resistant to or intolerant of prior therapy including imatinib; coverage and continuation details per product summary.

    Prerequisite Part D drug required; continuation of prior therapy approvable (chunk 134).

    inv-41: Dasatinib — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Dasatinib main criteria: Diagnosis of Ph+ CML (various phases) OR Philadelphia Chromosome‑Positive ALL (Ph+ALL) with documented resistance or intolerance to prior therapy (including imatinib) as applicable; prescriber must be a hematologist or oncologist; coverage duration 2 years.

    Prerequisite Part D drug required (chunk 137).

    inv-42: Daurismo — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Daurismo main criteria: Member has newly diagnosed acute myelogenous leukemia (AML) and the requested drug is being used with low‑dose cytarabine and the member is either ≥75 years of age or has comorbidities making intensive induction inappropriate; prescriber must be a hematologist or oncologist; coverage duration 2 years.

    From product summary (chunk 140).

    inv-43: Diacomit — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Diacomit main criteria: Documented diagnosis of seizures associated with Dravet syndrome AND concurrent use of clobazam; prescriber must be a neurologist; coverage duration 2 years.

    From product summary (chunk 143).

    inv-44: Dichlorphenamide Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Dichlorphenamide initial criteria: Member has a documented diagnosis of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, or related condition; coverage duration 2 years.

    From product summary (chunk 146).

    inv-45: Doptelet Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Doptelet initial criteria: Member has documented thrombocytopenia associated with chronic liver disease scheduled for a procedure OR thrombocytopenia with chronic immune thrombocytopenia (ITP) with insufficient response to prior therapy; coverage duration 2 years.

    Prerequisite Part D drug required (chunk 149).

    inv-46: Droxidopa Initial Therapy — Covered when ALL of the following are met

    Covered when ALL of the following are met:

    Droxidopa initial criteria: Member has a documented diagnosis of neurogenic orthostatic hypotension (NOH); coverage duration 2 years.

    From product summary (chunk 152).

    inv-47: Dupixent Indication-Specific Criteria — Covered when ALL applicable indication-specific criteria are met

    Covered when ALL applicable indication‑specific criteria are met:

    Dupixent atopic dermatitis criteria: Documented moderate‑to‑severe atopic dermatitis with trial and failure, contraindication, or intolerance to a minimum 30‑day supply (14 days for topical corticosteroids) of at least one appropriate topical/systemic therapy (medium+ potency topical corticosteroid, pimecrolimus, tacrolimus, or crisaborole); prescribed by or in consultation with specified specialists; coverage duration 2 years.

    Prerequisite Part D drug required for listed indications (chunks 155–156).

    Dupixent asthma criteria: Documented moderate‑to‑severe asthma with an eosinophilic phenotype or dependence on oral corticosteroids; prescribing specialist indicated; coverage duration per product summary.

    From product summary (chunks 155–156).

    No explicit exclusion criteria for Abilify Mycite are listed in this extract. The product entry indicates Off-Label Uses: N/A and Exclusion Criteria: N/A, and requires documented diagnosis and prior oral aripiprazole worsening for PA. (See product listing for full criteria.)

    No explicit exclusion criteria for Abiraterone are listed in this extract. The entry reports Off-Label Uses: N/A and Exclusion Criteria: N/A, and specifies required documentation that abiraterone is used in combination with prednisone for the approved prostate cancer indications.

    Off-label uses are not specified in this excerpt for the products shown. Where listed in the extract, Off-Label Uses are recorded as N/A for the product entries included here.

    For armodafinil/modafinil, the policy explicitly excludes use for generalized fatigue, jet lag, or sleep-deprivation not associated with a covered diagnosis. Covered indications in the entry are narcolepsy, excessive sleepiness associated with obstructive sleep apnea, and shift-work sleep disorder.

    Provider Actions — Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Abilify Mycite — submit PA with diagnosis and oral aripiprazole failure/worsening

    Abilify Mycite requires prior authorization. The provider must document a diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia and show worsening symptoms on oral aripiprazole; the prescribing physician must be a psychiatrist. Coverage duration is 2 years; a prerequisite Part D drug (oral aripiprazole) is required prior to approval.

    • Documented diagnosis (bipolar I disorder, major depressive disorder, or schizophrenia)
    • Documentation of worsening symptoms with oral aripiprazole
    • Prescriber must be a psychiatrist
    • Prerequisite Part D drug: oral aripiprazole required
    • Coverage duration: 2 years
    Prior Authorization

    Abiraterone — submit PA with diagnosis and combination therapy statement

    Submit prior authorization for abiraterone with documentation of metastatic castration‑resistant prostate cancer (CRPC) or metastatic high‑risk castration‑sensitive prostate cancer and that abiraterone is being used in combination with prednisone; prescriber must be an oncologist or urologist. Coverage duration is 2 years.

    Provider Actions — Additional Documentation, Step Therapy, and Denial Risks

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Step Therapy / Prerequisite Part D Drug Requirements

    DrugStep therapy requirement
    Abilify MyciteRequires prior use of oral aripiprazole (prerequisite Part D drug) with documentation of worsening symptoms on oral aripiprazole prior to approval
    ScopeStep therapy requirement
    Selected dermatologic and rheumatologic indications (e.g., plaque psoriasis, RA, PJIA, non-radiographic axial spondyloarthritis, enthesitis-related arthritis)Trial and failure, contraindication, or intolerance to specified conventional or topical therapies (examples: topical corticosteroids, vitamin D analogs, methotrexate, leflunomide, sulfasalazine) required prior to biologic coverage as specified by indication
    DrugStep therapy requirement / Thresholds
    ArikaycePrerequisite Part D drug required: member must have received a multidrug background regimen for a minimum of 6 consecutive months and not achieved at least two negative sputum cultures prior to Arikayce approval
    DrugStep therapy requirement
    Avmapki Fakzynja (co-pack)Prerequisite Part D drug required: criteria specify prior systemic therapy and presence of KRAS mutation; prior therapy must be documented prior to approval
    DrugStep therapy requirement
    BalversaPrerequisite Part D drug required: member must have progressed during/after at least one line of prior systemic therapy (and prior PD-1/PD-L1 therapy or be ineligible), documented before approval
    DrugsStep therapy requirement
    BosulifPrerequisite Part D drug required: criteria require prior therapy (e.g., prior TKI like imatinib) documented before approval
    BrukinsaPrerequisite Part D drug required for some indications: documentation of prior therapy (e.g., anti‑CD20 regimen) required prior to approval
    DrugsStep therapy requirement
    BrukinsaPrerequisite Part D drug required for some indications; prior therapy history must be documented (see product-specific criteria)
    CabometyxPrerequisite Part D drug required: prior VEGFR-targeted therapy or sorafenib failure/contraindication/intolerance must be documented per indication
    CalquencePrerequisite Part D drug required: prior therapy or ineligibility for standard therapy must be documented prior to approval
    IndicationsStep therapy requirement
    Non-radiographic axial spondyloarthritis and enthesitis-related arthritis (Cosentyx)Minimum one-month trial and failure, contraindication, or intolerance to two NSAIDs at maximally indicated doses required prior to approval
    DrugsStep therapy requirement
    DanzitenPrerequisite Part D drug required: criteria indicate prior therapy (e.g., imatinib) resistance or intolerance must be documented prior to approval
    DasatinibPrerequisite Part D drug required: documentation of resistance or intolerance to prior therapy (including imatinib where specified) required before approval
    DrugStep therapy requirement
    DopteletPrerequisite Part D drug required: documentation of prior therapies and indication-specific criteria required prior to approval
    DrugStep therapy requirement
    DupixentPrerequisite Part D drug required for listed indications: trial and failure/contraindication/intolerance to specified topical, inhaled, or systemic therapies must be documented per indication
    DrugStep therapy requirement
    EltrombopagPrerequisite Part D drug required: indication-specific prior therapies (e.g., corticosteroids, immunoglobulins, splenectomy for ITP) must be documented before approval
    General statementRequirement
    Document trials and outcomes where applicableDocument trial/failure, contraindication, or intolerance to specified prior conventional or listed therapies as required by the product-specific criteria
    DrugStep therapy requirement
    EucrisaInitial approval requires trial and failure, contraindication, or intolerance to one prescription-strength topical corticosteroid unless the affected area is sensitive (face, axillae, groin); reauthorization requires documented positive clinical response
    General statementRequirement
    Prerequisite Part D drugs (general)Some product criteria explicitly require use of a prerequisite Part D drug prior to approval; specific agent(s) may be listed in product-level criteria
    DrugStep therapy requirement
    TrulicityInitial therapy requires either prescriber documentation of Type 2 Diabetes OR a trial with a minimum 90-day supply of a listed oral antidiabetic agent/class (e.g., metformin-containing agent); reauthorization requires demonstration of positive clinical response
    ScopeNote
    Mixed product-level prerequisite Part D therapy indicatorsProduct entries vary: some (e.g., Hyrnuo, Ibrance, Iclusig) require prerequisite Part D drug use for certain indications, while others do not—refer to product-specific criteria
    ScopeNote
    Mixed statements across productsIndicates whether prerequisite Part D drug therapy is required varies by drug and indication; confirm requirement at the product-level criteria

    Continuation Criteria — Reauthorization and Response Requirements

    Coding and Key Clinical Thresholds

    inv-104: Minimum duration of prior multidrug background regimen — 6 months
    Minimum prior multidrug regimenMinimum of 6 consecutive months of a multidrug background regimen
    ContextApplies to Mycobacterium avium complex (MAC) lung disease prior to Arikayce consideration
    Prerequisite therapy flagUse of a background multidrug regimen is required (prerequisite Part D drug)
    inv-105: Sputum culture response requirement — Not achieving at least two negative sputum cultures
    Required sputum culture responseMember did not achieve at least two negative sputum cultures after treatment
    Associated indicationMycobacterium avium complex (MAC) lung disease

    Definitions and Term Clarifications

    inv-309: Abilify Mycite definition — ingestible sensor–enabled aripiprazole formulation
    DefinitionAbilify Mycite is an ingestible sensor–enabled formulation of aripiprazole
    Indications notedUsed for bipolar I disorder, major depressive disorder, or schizophrenia per required medical information
    Authorization notePrior authorization requires documentation of worsening symptoms on oral aripiprazole and psychiatrist prescriber
    inv-310: Abiraterone definition — androgen biosynthesis inhibitor indication summary
    DefinitionAbiraterone is an androgen biosynthesis inhibitor
    Indication summaryDocumented metastatic castration-resistant prostate cancer (CRPC) or metastatic high-risk castration-sensitive prostate cancer; used with prednisone

    Background — Scope and Document Notes

    This excerpt is a section of Harvard Pilgrim Health Care's prior authorization medical necessity guidelines summarizing product-specific prior authorization requirements for multiple biologic and specialty drugs. Each product entry includes the required documented diagnosis, any prerequisite therapy or Part D drug requirements, prescriber specialty restrictions where applicable, coverage durations (commonly 2 years), and specific exclusion statements when provided. Providers should consult the full product criteria for detailed documentation and step-therapy requirements before submitting a PA request.

    Biosimilar Products and Related PA Notes

    Note
    Policy Summary
    Payerharvard pilgrim health care
    PolicyPrior authorization medical necessity guidelines — formulary product listings (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 1, 2026
    Next Review DateN/A
    Key ActionPrescribers must submit prior authorization with documented diagnosis and required prior-therapy trials or specialist prescriber information as specified for each drug.
    SourceLink
    On This Page
    Coverage Criteria — Product-Specific RequirementsProvider Actions — Prior Authorization, Documentation, and Denial RisksProvider Actions — Additional Documentation, Step Therapy, and Denial RisksStep Therapy / Prerequisite Part D Drug RequirementsContinuation Criteria — Reauthorization and Response RequirementsCoding and Key Clinical ThresholdsDefinitions and Term ClarificationsBackground — Scope and Document NotesBiosimilar Products and Related PA Notes
    • Documented diagnosis: metastatic CRPC OR metastatic high‑risk castration‑sensitive prostate cancer
    • Statement that abiraterone is used in combination with prednisone
    • Prescriber must be an oncologist or urologist
    • Coverage duration: 2 years
    Prior Authorization

    Humira and biosimilars — PA and indication‑specific documentation required

    Prior authorization is required for listed Humira products and biosimilars. The provider must supply indication‑specific required medical information and, when specified, prescriber specialty or consultation documentation.

    • Documented diagnosis specific to the Humira indication (e.g., ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, RA, PJIA, hidradenitis suppurativa, uveitis)
    • For plaque psoriasis and certain indications, documentation of failed/intolerant trials of listed topical/systemic therapies
    • Prescriber specialty or consult where specified (dermatologist, gastroenterologist, ophthalmologist, rheumatologist)
    • Coverage duration typically 2 years
    Prior Authorization

    Aimovig — PA with migraine diagnosis; initial 6 months, then 2 years

    Aimovig requires prior authorization. For initial approval submit documented diagnosis of migraine; initial approval is 6 months and subsequent approvals 2 years. For continuation, provide documentation of clinically significant reduction in migraine days per month.

    • Documented diagnosis of migraine for initial approval
    • Initial approval duration: 6 months; subsequent approval: 2 years
    • For continuation: documented clinically significant reduction in migraine days per prescriber assessment
    Prior Authorization

    Akeega — PA with oncology diagnosis, BRCA status, and regimen details

    Akeega requires prior authorization. The provider must document metastatic prostate cancer with deleterious/suspected deleterious BRCA mutation and that the drug is being used in combination with prednisone per regimen; prescriber must be an oncologist. Coverage duration noted.

    • Documented diagnosis: metastatic prostate cancer with deleterious or suspected deleterious BRCA mutation
    • Statement that drug is used in combination with prednisone and regimen details as indicated
    • Prescriber must be an oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Alecensa — PA with documented ALK‑positive NSCLC or adjuvant indication

    Alecensa prior authorization required. Provide documentation of ALK‑positive metastatic NSCLC or adjuvant use after resection of ALK‑positive tumor; prescriber must be an oncologist. Coverage duration 2 years; no prerequisite Part D drug required.

    • Documented diagnosis: ALK‑positive metastatic NSCLC OR adjuvant use post resection of ALK‑positive tumor
    • Prescriber must be an oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Alunbrig — PA with ALK‑positive metastatic NSCLC and oncologist prescriber

    Alunbrig requires prior authorization. The provider must document ALK‑positive metastatic NSCLC and the prescriber must be an oncologist. Coverage duration is 2 years.

    • Documented diagnosis: ALK‑positive metastatic NSCLC
    • Prescriber must be an oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Alosetron — PA with documented severe diarrhea‑predominant IBS (female)

    Alosetron prior authorization required. Submit documentation of severe diarrhea‑predominant irritable bowel syndrome in a female patient. Coverage duration: 2 years.

    • Documented diagnosis: severe diarrhea‑predominant IBS in a female
    • Coverage duration: 2 years
    Prior Authorization

    Arcalyst — PA with indication‑specific diagnostic documentation

    Arcalyst requires prior authorization with indication‑specific documentation (e.g., CAPS, IL‑1 receptor antagonist deficiency, recurrent pericarditis). Coverage duration is 2 years.

    • Documented diagnosis per indication: CAPS (FCAS/Muckle‑Wells), IL‑1RA deficiency for maintenance in patients ≥10 kg, or recurrent pericarditis with indication‑specific justification
    • Coverage duration: 2 years
    Prior Authorization

    Arikayce — PA with MAC diagnosis and ≥6 months multidrug regimen failure documentation

    Arikayce prior authorization required. The provider must document MAC lung disease, that Arikayce is part of a combination antibacterial regimen, and that the patient did not achieve ≥2 negative sputum cultures after at least 6 consecutive months of a multidrug background regimen; specialist involvement may be required. Coverage duration 2 years.

    • Documented diagnosis: Mycobacterium avium complex (MAC) lung disease
    • Statement that Arikayce is used as part of a combination antibacterial regimen
    • Documentation that patient did not achieve ≥2 negative sputum cultures after ≥6 months of multidrug background regimen
    • Prescribed by or in consultation with an infectious disease or appropriate specialist
    • Coverage duration: 2 years
    Prior Authorization

    Armodafinil/Modafinil — PA with approved sleep disorder diagnosis; exclusions apply

    Armodafinil/Modafinil requires prior authorization. Submit documentation of narcolepsy, excessive sleepiness associated with obstructive sleep apnea, or shift‑work sleep disorder. Do not submit for generalized fatigue, jet‑lag, or sleep‑deprivation without a covered diagnosis.

    • Documented diagnosis: narcolepsy OR excessive sleepiness associated with OSA OR shift‑work sleep disorder
    • Exclusion: generalized fatigue, jet lag, or sleep‑deprivation not associated with a covered diagnosis
    • Coverage duration: 2 years
    Prior Authorization

    Augtyro — PA with NSCLC or NTRK fusion‑positive tumor diagnostic documentation

    Augtyro is subject to prior authorization for indicated uses. Provide documentation that the patient has NSCLC or an NTRK gene fusion–positive solid tumor that is locally advanced/metastatic or not amenable to surgery and has progressed or lacks satisfactory alternatives.

    • Documented diagnosis: NSCLC OR NTRK gene fusion–positive solid tumor that is locally advanced/metastatic or where surgery would cause severe morbidity
    • Documentation that disease has progressed following treatment or there is no satisfactory alternative therapy
    • Coverage duration and prescriber restrictions per full criteria
    Prior Authorization

    Augtyro — PA required for all indications; supply listed documentation

    Augtyro (all medically‑accepted indications) requires prior authorization with the required documentation as listed in the criteria.

    • Submit indication‑specific documentation for all requests per product criteria
    Prior Authorization

    Austedo — PA with diagnosis of tardive dyskinesia or Huntington’s chorea

    Austedo/Austedo XR require prior authorization. Document the diagnosis (tardive dyskinesia or chorea associated with Huntington’s disease) as specified.

    • Documented diagnosis: Tardive dyskinesia OR chorea associated with Huntington’s disease
    • Coverage and prescriber details per product criteria
    Prior Authorization

    Avmapki Fakzynja — PA with KRAS mutation and prior systemic therapy documentation

    Avmapki Fakzynja co‑pack requires prior authorization. Providers must document diagnosis (recurrent low‑grade serous ovarian cancer), presence of a KRAS mutation, and prior systemic therapy.

    • Documented diagnosis: recurrent low‑grade serous ovarian cancer (LGSOC)
    • Laboratory/proof of KRAS mutation
    • Documentation of prior systemic therapy received
    • Coverage duration: 2 years
    Prior Authorization

    Ayvakit — PA with mutation‑specific diagnosis and specialist prescriber

    Ayvakit requires prior authorization. The provider must document the specific indicated diagnosis (e.g., PDGFRA Exon 18 mutation‑positive unresectable/metastatic GIST or systemic mastocytosis) and the prescribing physician must be an allergist, immunologist, or specified specialist.

    • Documented diagnosis per indication (PDGFRA Exon 18 mutation‑positive unresectable/metastatic GIST; advanced systemic mastocytosis; indolent systemic mastocytosis)
    • Prescriber must be an allergist, immunologist, or specified specialist
    • Coverage duration: 2 years
    Prior Authorization

    Balversa — PA with FGFR3 alteration and prior therapy documentation

    Balversa requires prior authorization. Providers must document locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 alterations and prior systemic therapy; prior PD‑1/PD‑L1 therapy status must be documented.

    • Documented diagnosis: locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
    • Documentation of progression after at least one line of systemic therapy and prior PD‑1/PD‑L1 inhibitor exposure or ineligibility
    • Prescriber specialty per product criteria
    • Coverage duration: 2 years
    Prior Authorization

    Benlysta — PA: document active autoantibody‑positive SLE and concurrent standard therapy

    Benlysta prior authorization requires documented active, autoantibody‑positive systemic lupus erythematosus (or active lupus nephritis) and concurrent standard therapy; prescriber must be a nephrologist or rheumatologist. Benlysta is not approved as monotherapy or for certain severe disease states.

    • Documented active, autoantibody‑positive SLE (e.g., ANA, anti‑dsDNA, anti‑Sm) OR active lupus nephritis
    • Documentation of concurrent standard therapy (antimalarials, corticosteroids, or immunosuppressives)
    • Prescriber must be a nephrologist or rheumatologist
    • Exclusions: not approved as monotherapy, for severe active lupus nephritis or severe active CNS lupus, for autoantibody‑negative members, or in combination with other biologics/IV cyclophosphamide
    • Coverage duration: 2 years
    Documentation Required

    Benlysta — ensure required medical information and prescriber specialty are documented

    Benlysta prior authorization requires the medical documentation above and prescriber specialty (nephrologist or rheumatologist); absence of these may prevent approval.

    • See required documentation: active, autoantibody‑positive SLE or active lupus nephritis, concurrent standard therapy
    • Prescriber must be a nephrologist or rheumatologist
    Prior Authorization

    Berinert — PA: document HAE and allergist/immunologist prescriber

    Berinert prior authorization requires documentation of hereditary angioedema and that the prescriber be an allergist or immunologist.

    • Documented diagnosis of hereditary angioedema (HAE)
    • Prescriber must be an allergist or immunologist
    • Coverage duration: 2 years
    Prior Authorization

    Bexarotene gel — PA with documented CTCL and specialist prescriber

    Bexarotene gel prior authorization requires documentation of cutaneous T‑cell lymphoma and that the prescriber be an oncologist or dermatologist.

    • Documented diagnosis of cutaneous T‑cell lymphoma
    • Prescriber must be an oncologist or dermatologist
    • Coverage duration: 2 years
    Prior Authorization

    Bosulif — PA with Ph+ CML documentation and prerequisite Part D therapy

    Bosulif prior authorization requires documentation of Philadelphia chromosome‑positive CML per specified scenarios; a prerequisite Part D drug is required and prescriber must be a hematologist or oncologist.

    • Documented diagnosis: chronic phase Ph+ CML (newly‑diagnosed or resistant/intolerant to at least one prior therapy) OR accelerated/blast phase Ph+ CML
    • Prescriber must be a hematologist or oncologist
    • Prerequisite Part D drug required
    Prior Authorization

    Braftovi — PA with BRAF mutation, combination therapy details, and oncology prescriber

    Braftovi prior authorization requires documentation of BRAF V600E/V600K mutated disease and planned combination therapy per indication; prescriber must be an oncologist. Braftovi is not indicated for wild‑type BRAF disease.

    • Documented diagnosis per indication (metastatic CRC with BRAF V600E; unresectable/metastatic melanoma with BRAF V600E/V600K; metastatic NSCLC with BRAF V600E)
    • Planned combination therapy details (e.g., cetuximab, binimetinib)
    • Prescriber must be an oncologist
    • Exclusion: not indicated for wild‑type BRAF melanoma or wild‑type BRAF CRC
    • Coverage duration: 2 years
    Prior Authorization

    Brukinsa — PA with diagnosis, prior therapy history, and hematology/oncology prescriber

    Brukinsa prior authorization requires documented eligible hematologic malignancy with prior therapy history; prescriber must be a hematologist or oncologist and a prerequisite Part D drug is required for some indications.

    • Documented diagnosis per indicated hematologic malignancy (e.g., MCL with prior therapy, relapsed/refractory MZL after anti‑CD20 regimen, WM, CLL/SLL, relapsed FL with obinutuzumab)
    • Prescriber must be a hematologist or oncologist
    • Prerequisite Part D drug required for indicated uses
    • Coverage duration: 2 years
    Documentation Required

    Brukinsa — ensure diagnostic and prior‑therapy documentation

    Brukinsa prior authorization requires the specific diagnostic and prior‑therapy details and specialist prescriber; missing this documentation may prevent approval.

    • Provide documented diagnosis and prior therapies as specified for the requested indication
    • Prescriber must be a hematologist or oncologist
    Prior Authorization

    Cabometyx — PA with indication‑specific diagnosis and oncology prescriber

    Cabometyx prior authorization required. Document the diagnosis corresponding to the requested indication (e.g., advanced RCC, progressed DTC after VEGFR therapy, HCC after sorafenib), and prescriber must be an oncologist; prerequisite Part D drug may be required.

    • Documented diagnosis per indication (advanced RCC; DTC progressed after VEGFR therapy and RAI‑refractory/ineligible; HCC with sorafenib failure/contraindication/intolerance; pNET/epNET previously treated)
    • Prescriber must be an oncologist
    • Prerequisite Part D drug required per indication
    • Coverage duration: 2 years
    Prior Authorization

    Calquence — PA with hematologic diagnosis, prior therapy details, and specialist prescriber

    Calquence prior authorization required. Provide documentation of CLL/SLL or MCL with prior therapy or ineligibility for standard therapy; prescriber must be a hematologist or oncologist; a prerequisite Part D drug may be required.

    • Documented diagnosis: CLL/SLL OR MCL with at least one prior therapy or ineligible for standard therapy
    • Prescriber must be a hematologist or oncologist
    • Prerequisite Part D drug required for some indications
    • Coverage duration: 2 years
    Prior Authorization

    Caplyta — PA with documented mood disorder diagnosis

    Caplyta prior authorization required. Document diagnosis of bipolar depression or major depressive disorder (when used adjunctively); criteria indicate no prerequisite Part D drug is required.

    • Documented diagnosis: bipolar depression OR major depressive disorder (if used adjunctively with antidepressant)
    • No prerequisite Part D drug required per criteria
    Prior Authorization

    Caprelsa — PA with medullary thyroid cancer diagnosis and specialist prescriber

    Caprelsa prior authorization required. Document symptomatic or progressive medullary thyroid cancer with unresectable locally advanced disease; prescriber must be an endocrinologist or oncologist.

    • Documented diagnosis: symptomatic or progressive medullary thyroid cancer with unresectable locally advanced disease
    • Prescriber must be an endocrinologist or oncologist
    • No prerequisite Part D drug required
    • Coverage duration: 2 years
    Prior Authorization

    Carglumic Acid — PA with NAGS deficiency diagnostic documentation

    Carglumic Acid prior authorization required. Document chronic or acute hyperammonemia due to N‑acetylglutamate synthase (NAGS) deficiency.

    • Documented diagnosis: chronic or acute hyperammonemia due to NAGS deficiency
    • No prerequisite Part D drug required
    • Coverage duration: 2 years
    Prior Authorization

    Cayston — PA: document CF diagnosis and Pseudomonas in lungs

    Cayston prior authorization required. Providers must document a diagnosis of cystic fibrosis and evidence of Pseudomonas aeruginosa in the lungs; coverage duration 2 years. Lack of these diagnostics may lead to denial.

    • Documented diagnosis: cystic fibrosis
    • Evidence of Pseudomonas aeruginosa in the lungs (microbiologic or clinical)
    • Coverage duration: 2 years
    Denial Risk

    Cayston — missing diagnostic information may trigger denial

    Cayston prior authorization: ensure documentation of CF diagnosis and Pseudomonas aeruginosa evidence when submitting requests; absence may trigger denial.

    • Provide CF diagnosis and evidence of Pseudomonas aeruginosa in the lungs
    Prior Authorization

    Cobenfy Starter Pack — PA with schizophrenia diagnosis and psychiatrist prescriber

    Cobenfy Starter Pack requires prior authorization. Document a diagnosis of schizophrenia and that the prescribing physician is a psychiatrist; continuation of prior therapy may be approvable.

    • Documented diagnosis of schizophrenia
    • Prescriber must be a psychiatrist
    • Coverage duration: 2 years; continuation of prior therapy may be approved
    Prior Authorization

    Cometriq — PA with oncology diagnosis and oncologist prescriber

    Cometriq requires prior authorization. Document progressive, metastatic medullary thyroid cancer and that the prescriber is an oncologist.

    • Documented diagnosis: progressive, metastatic medullary thyroid cancer
    • Prescriber must be an oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Copiktra — PA with relapsed/refractory CLL/SLL and ≥2 prior therapies

    Copiktra prior authorization required. Document relapsed or refractory CLL/SLL with at least two prior therapies and that the prescriber is a hematologist or oncologist; absence of this history may lead to denial.

    • Documented diagnosis: relapsed or refractory CLL or SLL
    • Documentation of at least two prior therapies
    • Prescriber must be a hematologist or oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Cosentyx — PA with indication‑specific prior therapy trials and specialist involvement

    Cosentyx prior authorization requires indication‑specific documentation (e.g., failed topical/systemic therapies for plaque psoriasis; two NSAID trials for axial conditions) and that the prescriber be or consult with a dermatologist or rheumatologist; some indications require prerequisite Part D therapy.

    • Documented diagnosis per indication and prior therapy trials (e.g., failed topical/systemic agents for plaque psoriasis; minimum one‑month NSAID trials and failure/contraindication/intolerance to two NSAIDs for axial conditions)
    • Prescriber must be or consult with dermatologist or rheumatologist
    • Prerequisite Part D drug required in some indications
    • Coverage duration: 2 years
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    ImplicationIndicates inadequate microbiologic response to multidrug therapy prior to Arikayce
    inv-106: Pre-treatment blood eosinophil count — >= 1000 cells/microliter
    Pre-treatment eosinophil threshold>= 1000 cells/microliter
    Applicable indicationsSevere eosinophilic asthma, EGPA, or HES pathway per criteria
    Role in authorizationRequired laboratory value to meet Fasenra (anti-eosinophil) criteria
    inv-107: Minimum GH stimulation tests failed — at least TWO (initiation) or at least ONE (continuation after linear growth)
    GH stimulation test requirement (initiation)Failure of at least TWO GH stimulation tests
    GH stimulation test requirement (continuation after linear growth)Failure of at least ONE GH stimulation test after re-evaluation following completion of linear growth
    DocumentationX-ray evidence of open epiphyses and growth chart data required for pediatric GHD initiation/continuation
    inv-108: AIDS Wasting weight loss threshold — >= 10% weight loss from baseline OR BMI < 20
    AIDS wasting weight-loss threshold>= 10% weight loss from baseline OR BMI < 20
    Associated diagnosisDocumented diagnosis of AIDS required
    Use caseApplies to GH therapy consideration in AIDS wasting indication
    inv-109: Height and IGF-1 SDS thresholds — height SDS <= -3.0; basal IGF-1 SDS <= -3.0
    Height SDS thresholdHeight standard deviation score (SDS) ≤ -3.0
    Basal IGF-1 SDS thresholdBasal IGF-1 SDS ≤ -3.0
    Additional requirementsNormal or elevated GH level or GH gene deletion, radiographs documenting open epiphyses, and exclusion of secondary causes
    Prescriber requirementPrescribing physician must be an oncologist or urologist per PA notes
    inv-311: Required Medical Information — clinical details prescriber must document
    Required medical information (general)Documented diagnosis specific to the indication is required (see product-specific nodes)
    Prior therapy documentationWhen applicable, documentation of prior trials, failures, contraindications, or intolerance to specified therapies must be provided
    Prescriber specialtyPrescribing physician specialty or consultation required where specified (e.g., oncologist, endocrinologist, neurologist)
    inv-312: ALK-positive metastatic NSCLC — definition used for Alecensa/Alunbrig
    DefinitionALK-positive metastatic NSCLC: anaplastic lymphoma kinase–positive metastatic non–small cell lung cancer
    Authorization contextDocumented ALK-positive metastatic NSCLC required for Alecensa and Alunbrig PA; prescriber must be an oncologist
    Adjuvant useAlecensa may also be used as adjuvant treatment following resection of ALK-positive tumor (documented)
    inv-313: MAC lung disease — Mycobacterium avium complex lung disease definition
    DefinitionMycobacterium avium complex (MAC) lung disease — pulmonary infection caused by MAC organisms
    Authorization criteriaArikayce authorized as part of combination antibacterial regimen when patient fails to achieve ≥2 negative sputum cultures after ≥6 months of multidrug therapy
    Required evidenceDocumentation of MAC lung disease diagnosis and microbiologic response (sputum cultures) required for PA
    inv-314: NTRK gene fusion–positive tumors — definition used for Augtyro
    DefinitionNTRK gene fusion–positive tumors: solid tumors harboring neurotrophic tyrosine receptor kinase gene fusions
    Authorization contextEligible for TRK inhibitor (Augtyro) when locally advanced/metastatic or when surgery would cause severe morbidity and no satisfactory alternative therapy exists
    DocumentationRequired documentation of NTRK fusion status and advanced/metastatic disease per PA notes
    inv-315: FGFR3 genetic alterations — definition used for Balversa
    DefinitionFGFR3 genetic alterations: susceptible FGFR3 alterations in urothelial carcinoma conferring sensitivity to FGFR-targeted therapy
    Authorization contextBalversa requires documented susceptible FGFR3 alteration and prior systemic therapy progression
    PrescriberPrescribing physician typically an oncologist or urologist per PA notes
    inv-316: autoantibody-positive SLE — definition used for Benlysta
    DefinitionAutoantibody-positive SLE: systemic lupus erythematosus with positive autoantibodies (e.g., ANA, anti-ds-DNA, anti-Sm)
    Authorization requirementBenlysta requires documented active, autoantibody-positive SLE or active lupus nephritis and concurrent standard therapy
    ExclusionsBenlysta not approved as monotherapy, in autoantibody-negative members, or for severe active lupus nephritis/CNS lupus
    inv-317: BRAF V600E/V600K mutation — definition used for Braftovi
    DefinitionBRAF V600E/V600K mutation: activating BRAF gene mutations identifying patients for targeted therapy
    Authorization contextRequired for Braftovi and Cotellic use in specified melanoma/CRC/NSCLC indications with combination regimens
    Exclusion noteTherapies not indicated for wild-type BRAF disease per product-specific exclusions
    inv-318: Mantle Cell Lymphoma (MCL) — definition used for Brukinsa
    DefinitionMantle Cell Lymphoma (MCL): a B-cell non-Hodgkin lymphoma
    Authorization contextBrukinsa coverage requires documented MCL and prior therapy in certain indications; prescriber must be hematologist/oncologist
    Prior therapyAt least one prior therapy required for MCL indication per PA notes
    inv-319: Evidence of Pseudomonas aeruginosa — microbiologic/clinical evidence required for Cayston
    Evidence requiredMicrobiologic or clinical evidence of Pseudomonas aeruginosa in the lungs
    Associated productRequired for Cayston authorization in cystic fibrosis patients
    DocumentationProvider must document CF diagnosis and presence of Pseudomonas aeruginosa
    inv-320: BRAF V600E or V600K mutation — definition used for Cotellic
    Mutation requirementBRAF V600E or V600K mutation required for Cotellic when used with vemurafenib
    IndicationUnresectable or metastatic melanoma or histiocytic neoplasm per product notes
    PrescriberPrescribing physician must be an oncologist
    inv-321: Dravet syndrome-associated seizures — definition used for Diacomit
    DefinitionDravet syndrome–associated seizures: seizures occurring in patients with Dravet syndrome
    Concomitant therapyDiacomit requires concurrent use of clobazam per PA notes
    PrescriberPrescribing physician must be a neurologist
    inv-322: Subsequent Approval — definition reference for continuation criteria
    DefinitionSubsequent Approval: continuation requires documented clinical benefit such as reduction in migraine days or other outcome measures
    ExampleEmgality subsequent approval requires clinically significant reduction in migraine days per month
    UseApplied across multiple products for reauthorization criteria in this document
    inv-323: Idiopathic pulmonary fibrosis (IPF) — definition used for pirfenidone (Esbriet)
    DefinitionIdiopathic pulmonary fibrosis (IPF): chronic fibrotic lung disease; required documented diagnosis for pirfenidone (Esbriet)
    AuthorizationPirfenidone PA requires documented diagnosis of IPF
    Prerequisite therapyCriteria does not require a prerequisite Part D drug for Esbriet
    inv-324: Prostate cancer diagnostic terms — non-metastatic castration-resistant and metastatic hormone-sensitive prostate cancer definitions used for Erleada
    DefinitionsNon-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer as diagnostic terms for Erleada
    AuthorizationErleada requires documented diagnosis of one of these prostate cancer states and oncologist/urologist prescriber
    Coverage duration2 years per product notes
    inv-325: Advanced HR+ HER2- breast cancer — definition used for everolimus tablets
    DefinitionAdvanced HR+ HER2- breast cancer: hormone receptor–positive, HER2-negative advanced breast cancer requiring prior aromatase inhibitor failure and postmenopausal status for everolimus tablets
    Authorization contextEverolimus tablets require documented advanced HR+ HER2- disease with prior therapy failure as specified
    PrescriberPrescribing physician must be a neurologist or oncologist depending on indication
    inv-326: HES — Hypereosinophilic syndrome definition used in criteria
    DefinitionHES (Hypereosinophilic Syndrome): HES without an identifiable non-hematologic secondary cause
    ExclusionsHES with identifiable non-hematologic secondary cause (e.g., drug hypersensitivity, parasitic infection, HIV, non-hematologic malignancy) excluded from this pathway
    AuthorizationApplies to Fasenra/Fasenra Pen criteria in the document
    inv-327: Non-resistant EGFR mutation — definition used for Gilotrif
    DefinitionNon-resistant EGFR mutation: EGFR mutation status excluding known resistant mutations for Gilotrif use
    Authorization contextGilotrif requires documented non-resistant EGFR mutations for metastatic NSCLC per PA notes
    PrescriberPrescribing physician must be an oncologist
    inv-328: Pediatric GHD initiation criteria — definition used for Genotropin
    Pediatric GHD initiation criteria (summary)Open epiphyses on X-ray; failed response to at least TWO GH stimulation tests; gender-specific delayed bone age; height >2 SD below mean at initiation
    Continuation documentationGrowth chart, medical history, continuing care plan, and improvement in annualized pre-treatment growth rate after 6 months required
    Age/other indicationsAlso includes criteria for acquired GHD, AIDS wasting, and short bowel syndrome per product notes
    inv-329: Hereditary Angioedema (HAE) Types 1 & 2 — laboratory confirmation requirements
    HAE Types 1 & 2 confirmationDiagnosis must be confirmed by laboratory testing (e.g., low C4 level, reduced C1 esterase inhibitor level or function)
    AuthorizationRequired for icatibant and other HAE therapies per PA notes
    PrescriberPrescribing physician must be an allergist, hematologist, or immunologist for certain HAE agents
    inv-330: T315I-positive — mutation definition used for Iclusig
    DefinitionT315I-positive: presence of the T315I BCR-ABL mutation
    Authorization contextIclusig PA includes T315I-positive disease as a listed indication requiring documentation
    PrescriberPrescribing physician must be a hematologist or oncologist
    inv-331: IDH2 mutation — definition used for Idhifa
    DefinitionIDH2 mutation: isocitrate dehydrogenase-2 mutation associated with relapsed/refractory AML
    AuthorizationIdhifa requires documented IDH2 mutation in relapsed/refractory AML per PA notes
    PrescriberPrescribing physician must be a hematologist or oncologist
    inv-332: Severe primary IGF-1 deficiency — definition used for Increlex
    DefinitionSevere primary IGF-1 deficiency: height SDS ≤ -3.0 and basal IGF-1 SDS ≤ -3.0 with normal/elevated GH or GH gene deletion and neutralizing antibodies to GH
    Authorization requirementsRadiographs documenting open epiphyses, exclusion of secondary causes, age ≥2 years, and endocrinologist prescriber required for Increlex
    ExclusionsSecondary forms of IGF-1 deficiency (GH deficiency, malnutrition, hypothyroidism, chronic steroid therapy) excluded